 |
PDBsum entry 3c8b
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
3c8b
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.24.69
- bontoxilysin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on small molecule substrates.
|
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zn(2+)
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
283:18883-18891
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A.
|
|
D.Kumaran,
R.Rawat,
M.L.Ludivico,
S.A.Ahmed,
S.Swaminathan.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins
cleave specific soluble N-ethylmaleimide-sensitive factor attachment protein
receptor complex proteins and block the release of neurotransmitters that cause
flaccid paralysis and are considered potential bioweapons. Botulinum neurotoxin
type A is the most potent among the clostridial neurotoxins, and to date there
is no post-exposure therapeutic intervention available. To develop inhibitors
leading to drug design, it is imperative that critical interactions between the
enzyme and the substrate near the active site are known. Although
enzyme-substrate interactions at exosites away from the active site are mapped
in detail for botulinum neurotoxin type A, information about the active site
interactions is lacking. Here, we present the crystal structures of botulinum
neurotoxin type A catalytic domain in complex with four inhibitory substrate
analog tetrapeptides, viz. RRGC, RRGL, RRGI, and RRGM at resolutions of 1.6-1.8
A. These structures show for the first time the interactions between the
substrate and enzyme at the active site and delineate residues important for
substrate stabilization and catalytic activity. We show that OH of Tyr(366) and
NH(2) of Arg(363) are hydrogen-bonded to carbonyl oxygens of P1 and P1' of the
substrate analog and position it for catalytic activity. Most importantly, the
nucleophilic water is replaced by the amino group of the N-terminal residue of
the tetrapeptide. Furthermore, the S1' site is formed by Phe(194), Thr(215),
Thr(220), Asp(370), and Arg(363). The K(i) of the best inhibitory tetrapeptide
is 157 nm.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
FIGURE 4. Schematic diagram of molecular interactions
between Balc424 and tetrapeptide inhibitors. The interactions
between Balc424 active site residues and inhibitor peptides are
shown. A, RRGC; B, RRGM; C, RRGL; and D, RRGI. Black, red, blue,
yellow, and green colored circles represent carbon, oxygen,
nitrogen, sulfur, and sodium atoms, respectively. For clarity,
zinc coordination and water molecules involved in the
interactions at the active site are not shown. The figure was
prepared with Ligplot (47).
|
 |
Figure 7.
FIGURE 7. Electrostatic potential surface representation of
active site cavity. Models of RRGC (green), RRGM (light green),
RRGL (coral), and RRGI (magenta) with sulfate ions are
superposed. Red and blue indicate negative ( -0.5 V) and positive (
+0.5
V) electrostatic potential. The figure was prepared with CCP4MG
(50). The orientation is similar to Fig. 3A.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2008,
283,
18883-18891)
copyright 2008.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.Li,
R.Pai,
S.C.Cardinale,
M.M.Butler,
N.P.Peet,
D.T.Moir,
S.Bavari,
and
T.L.Bowlin
(2010).
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.
|
| |
J Med Chem,
53,
2264-2276.
|
 |
|
|
|
|
 |
J.E.Zuniga,
J.T.Hammill,
O.Drory,
J.E.Nuss,
J.C.Burnett,
R.Gussio,
P.Wipf,
S.Bavari,
and
A.T.Brunger
(2010).
Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.
|
| |
PLoS One,
5,
e11378.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Gul,
L.A.Smith,
and
S.A.Ahmed
(2010).
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
|
| |
PLoS One,
5,
e12872.
|
 |
|
|
|
|
 |
R.K.Dhaked,
M.K.Singh,
P.Singh,
and
P.Gupta
(2010).
Botulinum toxin: bioweapon & magic drug.
|
| |
Indian J Med Res,
132,
489-503.
|
 |
|
|
|
|
 |
S.I.Toth,
L.A.Smith,
and
S.A.Ahmed
(2009).
Extreme sensitivity of botulinum neurotoxin domains towards mild agitation.
|
| |
J Pharm Sci,
98,
3302-3311.
|
 |
|
|
|
|
 |
T.Xu,
L.Zhang,
X.Wang,
D.Wei,
and
T.Li
(2009).
Structure-based substrate screening for an enzyme.
|
| |
BMC Bioinformatics,
10,
257.
|
 |
|
|
|
|
 |
D.Kumaran,
R.Rawat,
S.A.Ahmed,
and
S.Swaminathan
(2008).
Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
|
| |
PLoS Pathog,
4,
e1000165.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Agarwal,
and
S.Swaminathan
(2008).
SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.
|
| |
J Biol Chem,
283,
25944-25951.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |